Prognostic value of ASXL1 mutations in patients with primary myelofibrosis and its relationship with clinical features: a meta-analysis
Additional sex combs like 1 (ASXL1) mutations are one of the most common molecular biological abnormalities in patients with primary myelofibrosis (PMF), and the effect of these mutations on prognosis remains controversial. Hence, we conducted a meta-analysis to assess the prognostic value and clini...
Gespeichert in:
| Veröffentlicht in: | Annals of hematology 2021-02, Vol.100 (2), p.465-479 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 479 |
|---|---|
| container_issue | 2 |
| container_start_page | 465 |
| container_title | Annals of hematology |
| container_volume | 100 |
| creator | Wang, Ziqing Liu, Weiyi Wang, Mingjing Li, Yujin Wang, Xueying Yang, Erpeng Ming, Jing Quan, Richeng Hu, Xiaomei |
| description | Additional sex combs like 1 (ASXL1) mutations are one of the most common molecular biological abnormalities in patients with primary myelofibrosis (PMF), and the effect of these mutations on prognosis remains controversial. Hence, we conducted a meta-analysis to assess the prognostic value and clinical characteristics of ASXL1 mutations in PMF patients. Eligible studies were systematically searched from PubMed, Embase, and the Cochrane Library. We extracted the hazard ratios (HRs) and their 95% confidence intervals (CIs) of overall survival (OS) and leukemia-free survival (LFS), the number of patients transformed to acute leukemia, and clinical characteristics to carry out a meta-analysis by fixed effect model or random effect model according to the heterogeneity between studies. A total of 4501 PMF patients from 16 cohorts of 14 studies were included in this meta-analysis. The results revealed that ASXL1 mutations might predict a shorter OS (HR = 2.30, 95% CI: 1.79–2.94,
P |
| doi_str_mv | 10.1007/s00277-020-04387-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7817569</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2474845601</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-d721fe2038346fedf4609d624ee73d86a9e14d09c250d76eb833ec454340b3ca3</originalsourceid><addsrcrecordid>eNp9kcuKFDEUhoMoTtv6Ai4k4MZN6cmlKlUuhGHwBg0KKrgL6dSp7gyppE2qRvoJfG0zU-14WZhNAuf7T85_fkIeM3jOANSLDMCVqoBDBVK0qlJ3yIpJwSuoW3mXrKATXVWXc0Ye5HwJwHgr-X1yJoRom07IFfnxMcVdiHlyll4ZPyONAz3_9HXD6DhPZnIxZOoCPZQnhinT727a00Nyo0lHOh7Rx8FtU8wuUxN66gqS0C_CvTssvPUuOGs8HdBMc8L8kho64mQqE4w_FvFDcm8wPuOj070mX968_nzxrtp8ePv-4nxTWankVPWKswE5iFbIZsB-kA10fcMlohJ925gOmeyhs7yGXjW4bYVAK2spJGyFNWJNXi19D_N2xN4WT8l4fTKko3H670pwe72LV1q1TNVlZ2vy7NQgxW8z5kmPLlv03gSMc9a8zNnKugFW0Kf_oJdxTsXwDdVxziS7pvhC2bLFnHC4HYaBvs5ZLznrkrO-yVmrInryp41bya9gCyAWIJdS2GH6_fd_2v4EDpi2bw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2479221411</pqid></control><display><type>article</type><title>Prognostic value of ASXL1 mutations in patients with primary myelofibrosis and its relationship with clinical features: a meta-analysis</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Wang, Ziqing ; Liu, Weiyi ; Wang, Mingjing ; Li, Yujin ; Wang, Xueying ; Yang, Erpeng ; Ming, Jing ; Quan, Richeng ; Hu, Xiaomei</creator><creatorcontrib>Wang, Ziqing ; Liu, Weiyi ; Wang, Mingjing ; Li, Yujin ; Wang, Xueying ; Yang, Erpeng ; Ming, Jing ; Quan, Richeng ; Hu, Xiaomei</creatorcontrib><description>Additional sex combs like 1 (ASXL1) mutations are one of the most common molecular biological abnormalities in patients with primary myelofibrosis (PMF), and the effect of these mutations on prognosis remains controversial. Hence, we conducted a meta-analysis to assess the prognostic value and clinical characteristics of ASXL1 mutations in PMF patients. Eligible studies were systematically searched from PubMed, Embase, and the Cochrane Library. We extracted the hazard ratios (HRs) and their 95% confidence intervals (CIs) of overall survival (OS) and leukemia-free survival (LFS), the number of patients transformed to acute leukemia, and clinical characteristics to carry out a meta-analysis by fixed effect model or random effect model according to the heterogeneity between studies. A total of 4501 PMF patients from 16 cohorts of 14 studies were included in this meta-analysis. The results revealed that ASXL1 mutations might predict a shorter OS (HR = 2.30, 95% CI: 1.79–2.94,
P
< 0.00001) and a higher probability of transformation to acute leukemia (LFS: HR = 1.77, 95% CI: 1.30–2.42,
P
= 0.0003; the rate of acute leukemia transformation: OR = 2.06, 95% CI: 1.50–2.83,
P
< 0.00001). Furthermore, ASXL1 mutations were correlated with patients older than 65 years old, male, a lower level of platelet counts, and a higher risk of the international prognostic score system. These findings indicate that ASXL1 mutations have a significant adverse impact on the prognosis of PMF patients and may contribute to risk stratification and prognostic assessment for PMF patients.</description><identifier>ISSN: 0939-5555</identifier><identifier>ISSN: 1432-0584</identifier><identifier>EISSN: 1432-0584</identifier><identifier>DOI: 10.1007/s00277-020-04387-7</identifier><identifier>PMID: 33386934</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Acute Disease ; Age Factors ; Aged ; Carcinogenesis - genetics ; Disease-Free Survival ; Female ; Hematology ; Humans ; Leukemia ; Leukemia - genetics ; Leukemia - mortality ; Male ; Medical prognosis ; Medicine ; Medicine & Public Health ; Meta-analysis ; Mutation ; Neoplasm Proteins - genetics ; Oncology ; Original ; Original Article ; Primary Myelofibrosis - genetics ; Primary Myelofibrosis - mortality ; Repressor Proteins - genetics ; Sex Factors ; Survival Rate</subject><ispartof>Annals of hematology, 2021-02, Vol.100 (2), p.465-479</ispartof><rights>The Author(s) 2021</rights><rights>The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-d721fe2038346fedf4609d624ee73d86a9e14d09c250d76eb833ec454340b3ca3</citedby><cites>FETCH-LOGICAL-c474t-d721fe2038346fedf4609d624ee73d86a9e14d09c250d76eb833ec454340b3ca3</cites><orcidid>0000-0002-7955-7041</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00277-020-04387-7$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00277-020-04387-7$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33386934$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Ziqing</creatorcontrib><creatorcontrib>Liu, Weiyi</creatorcontrib><creatorcontrib>Wang, Mingjing</creatorcontrib><creatorcontrib>Li, Yujin</creatorcontrib><creatorcontrib>Wang, Xueying</creatorcontrib><creatorcontrib>Yang, Erpeng</creatorcontrib><creatorcontrib>Ming, Jing</creatorcontrib><creatorcontrib>Quan, Richeng</creatorcontrib><creatorcontrib>Hu, Xiaomei</creatorcontrib><title>Prognostic value of ASXL1 mutations in patients with primary myelofibrosis and its relationship with clinical features: a meta-analysis</title><title>Annals of hematology</title><addtitle>Ann Hematol</addtitle><addtitle>Ann Hematol</addtitle><description>Additional sex combs like 1 (ASXL1) mutations are one of the most common molecular biological abnormalities in patients with primary myelofibrosis (PMF), and the effect of these mutations on prognosis remains controversial. Hence, we conducted a meta-analysis to assess the prognostic value and clinical characteristics of ASXL1 mutations in PMF patients. Eligible studies were systematically searched from PubMed, Embase, and the Cochrane Library. We extracted the hazard ratios (HRs) and their 95% confidence intervals (CIs) of overall survival (OS) and leukemia-free survival (LFS), the number of patients transformed to acute leukemia, and clinical characteristics to carry out a meta-analysis by fixed effect model or random effect model according to the heterogeneity between studies. A total of 4501 PMF patients from 16 cohorts of 14 studies were included in this meta-analysis. The results revealed that ASXL1 mutations might predict a shorter OS (HR = 2.30, 95% CI: 1.79–2.94,
P
< 0.00001) and a higher probability of transformation to acute leukemia (LFS: HR = 1.77, 95% CI: 1.30–2.42,
P
= 0.0003; the rate of acute leukemia transformation: OR = 2.06, 95% CI: 1.50–2.83,
P
< 0.00001). Furthermore, ASXL1 mutations were correlated with patients older than 65 years old, male, a lower level of platelet counts, and a higher risk of the international prognostic score system. These findings indicate that ASXL1 mutations have a significant adverse impact on the prognosis of PMF patients and may contribute to risk stratification and prognostic assessment for PMF patients.</description><subject>Acute Disease</subject><subject>Age Factors</subject><subject>Aged</subject><subject>Carcinogenesis - genetics</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Hematology</subject><subject>Humans</subject><subject>Leukemia</subject><subject>Leukemia - genetics</subject><subject>Leukemia - mortality</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Meta-analysis</subject><subject>Mutation</subject><subject>Neoplasm Proteins - genetics</subject><subject>Oncology</subject><subject>Original</subject><subject>Original Article</subject><subject>Primary Myelofibrosis - genetics</subject><subject>Primary Myelofibrosis - mortality</subject><subject>Repressor Proteins - genetics</subject><subject>Sex Factors</subject><subject>Survival Rate</subject><issn>0939-5555</issn><issn>1432-0584</issn><issn>1432-0584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kcuKFDEUhoMoTtv6Ai4k4MZN6cmlKlUuhGHwBg0KKrgL6dSp7gyppE2qRvoJfG0zU-14WZhNAuf7T85_fkIeM3jOANSLDMCVqoBDBVK0qlJ3yIpJwSuoW3mXrKATXVWXc0Ye5HwJwHgr-X1yJoRom07IFfnxMcVdiHlyll4ZPyONAz3_9HXD6DhPZnIxZOoCPZQnhinT727a00Nyo0lHOh7Rx8FtU8wuUxN66gqS0C_CvTssvPUuOGs8HdBMc8L8kho64mQqE4w_FvFDcm8wPuOj070mX968_nzxrtp8ePv-4nxTWankVPWKswE5iFbIZsB-kA10fcMlohJ925gOmeyhs7yGXjW4bYVAK2spJGyFNWJNXi19D_N2xN4WT8l4fTKko3H670pwe72LV1q1TNVlZ2vy7NQgxW8z5kmPLlv03gSMc9a8zNnKugFW0Kf_oJdxTsXwDdVxziS7pvhC2bLFnHC4HYaBvs5ZLznrkrO-yVmrInryp41bya9gCyAWIJdS2GH6_fd_2v4EDpi2bw</recordid><startdate>20210201</startdate><enddate>20210201</enddate><creator>Wang, Ziqing</creator><creator>Liu, Weiyi</creator><creator>Wang, Mingjing</creator><creator>Li, Yujin</creator><creator>Wang, Xueying</creator><creator>Yang, Erpeng</creator><creator>Ming, Jing</creator><creator>Quan, Richeng</creator><creator>Hu, Xiaomei</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-7955-7041</orcidid></search><sort><creationdate>20210201</creationdate><title>Prognostic value of ASXL1 mutations in patients with primary myelofibrosis and its relationship with clinical features: a meta-analysis</title><author>Wang, Ziqing ; Liu, Weiyi ; Wang, Mingjing ; Li, Yujin ; Wang, Xueying ; Yang, Erpeng ; Ming, Jing ; Quan, Richeng ; Hu, Xiaomei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-d721fe2038346fedf4609d624ee73d86a9e14d09c250d76eb833ec454340b3ca3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Acute Disease</topic><topic>Age Factors</topic><topic>Aged</topic><topic>Carcinogenesis - genetics</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Hematology</topic><topic>Humans</topic><topic>Leukemia</topic><topic>Leukemia - genetics</topic><topic>Leukemia - mortality</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Meta-analysis</topic><topic>Mutation</topic><topic>Neoplasm Proteins - genetics</topic><topic>Oncology</topic><topic>Original</topic><topic>Original Article</topic><topic>Primary Myelofibrosis - genetics</topic><topic>Primary Myelofibrosis - mortality</topic><topic>Repressor Proteins - genetics</topic><topic>Sex Factors</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Ziqing</creatorcontrib><creatorcontrib>Liu, Weiyi</creatorcontrib><creatorcontrib>Wang, Mingjing</creatorcontrib><creatorcontrib>Li, Yujin</creatorcontrib><creatorcontrib>Wang, Xueying</creatorcontrib><creatorcontrib>Yang, Erpeng</creatorcontrib><creatorcontrib>Ming, Jing</creatorcontrib><creatorcontrib>Quan, Richeng</creatorcontrib><creatorcontrib>Hu, Xiaomei</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Annals of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Ziqing</au><au>Liu, Weiyi</au><au>Wang, Mingjing</au><au>Li, Yujin</au><au>Wang, Xueying</au><au>Yang, Erpeng</au><au>Ming, Jing</au><au>Quan, Richeng</au><au>Hu, Xiaomei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic value of ASXL1 mutations in patients with primary myelofibrosis and its relationship with clinical features: a meta-analysis</atitle><jtitle>Annals of hematology</jtitle><stitle>Ann Hematol</stitle><addtitle>Ann Hematol</addtitle><date>2021-02-01</date><risdate>2021</risdate><volume>100</volume><issue>2</issue><spage>465</spage><epage>479</epage><pages>465-479</pages><issn>0939-5555</issn><issn>1432-0584</issn><eissn>1432-0584</eissn><abstract>Additional sex combs like 1 (ASXL1) mutations are one of the most common molecular biological abnormalities in patients with primary myelofibrosis (PMF), and the effect of these mutations on prognosis remains controversial. Hence, we conducted a meta-analysis to assess the prognostic value and clinical characteristics of ASXL1 mutations in PMF patients. Eligible studies were systematically searched from PubMed, Embase, and the Cochrane Library. We extracted the hazard ratios (HRs) and their 95% confidence intervals (CIs) of overall survival (OS) and leukemia-free survival (LFS), the number of patients transformed to acute leukemia, and clinical characteristics to carry out a meta-analysis by fixed effect model or random effect model according to the heterogeneity between studies. A total of 4501 PMF patients from 16 cohorts of 14 studies were included in this meta-analysis. The results revealed that ASXL1 mutations might predict a shorter OS (HR = 2.30, 95% CI: 1.79–2.94,
P
< 0.00001) and a higher probability of transformation to acute leukemia (LFS: HR = 1.77, 95% CI: 1.30–2.42,
P
= 0.0003; the rate of acute leukemia transformation: OR = 2.06, 95% CI: 1.50–2.83,
P
< 0.00001). Furthermore, ASXL1 mutations were correlated with patients older than 65 years old, male, a lower level of platelet counts, and a higher risk of the international prognostic score system. These findings indicate that ASXL1 mutations have a significant adverse impact on the prognosis of PMF patients and may contribute to risk stratification and prognostic assessment for PMF patients.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>33386934</pmid><doi>10.1007/s00277-020-04387-7</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0002-7955-7041</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0939-5555 |
| ispartof | Annals of hematology, 2021-02, Vol.100 (2), p.465-479 |
| issn | 0939-5555 1432-0584 1432-0584 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7817569 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Acute Disease Age Factors Aged Carcinogenesis - genetics Disease-Free Survival Female Hematology Humans Leukemia Leukemia - genetics Leukemia - mortality Male Medical prognosis Medicine Medicine & Public Health Meta-analysis Mutation Neoplasm Proteins - genetics Oncology Original Original Article Primary Myelofibrosis - genetics Primary Myelofibrosis - mortality Repressor Proteins - genetics Sex Factors Survival Rate |
| title | Prognostic value of ASXL1 mutations in patients with primary myelofibrosis and its relationship with clinical features: a meta-analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T12%3A55%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20value%20of%20ASXL1%20mutations%20in%20patients%20with%20primary%20myelofibrosis%20and%20its%20relationship%20with%20clinical%20features:%20a%20meta-analysis&rft.jtitle=Annals%20of%20hematology&rft.au=Wang,%20Ziqing&rft.date=2021-02-01&rft.volume=100&rft.issue=2&rft.spage=465&rft.epage=479&rft.pages=465-479&rft.issn=0939-5555&rft.eissn=1432-0584&rft_id=info:doi/10.1007/s00277-020-04387-7&rft_dat=%3Cproquest_pubme%3E2474845601%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2479221411&rft_id=info:pmid/33386934&rfr_iscdi=true |